CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 167 enrolled
Drug / intervention
Manzanilla Sophia® +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06859476
NCT06859476Phase 4Completed
CompareCT.gov

Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes

Laboratorios Sophia S.A de C.V.·interventional·Posted Mar 5, 2025·Updated Apr 8, 2026

In Brief

A Phase 4 clinical trial evaluating Manzanilla Sophia® and Meticel Ofteno® 0.5% for Ophthalmological Agent Toxicity. Completed, enrolled 167 participants across 1 site.

Detailed Summary

Demonstrate the non-inferiority of Manzanilla Sophia® compared to Meticel Ofteno® 0.5% in providing a sensation of eye relief, through the score of an analogous visual test for eye fatigue.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOphthalmological Agent Toxicity
CountriesMexico
Collaborators--

Timeline

Phase 4CompletedFinished
2026
First PostedMar 5, 2025
Enrollment StartMay 23, 2025
Primary CompletionSep 23, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.3 years ago

Interventions

Manzanilla Sophia®drug

Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.

Meticel Ofteno® 0.5%drug

Ophthalmic solution. Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco, Mexico. Route of Administration: Ophthalmic.